Covaxin: DCGI's expert panel approves Bharat Biotech's Phase 3 efficacy trial data1 min read 22 Jun 2021, 03:14 PM IST
According to the data submitted, Covaxin has shown the efficacy of 77.8% from the trial conducted on 25,800 subjects
The meeting took place before the company's 'pre-submission' meeting on Wednesday with WHO
The Subject Expert Committee (SEC) under India's drug regulator on Tuesday approved Bharat Biotech' phase-3 trial efficacy data for its Covid-19 vaccine 'Covaxin.'
Select your Category